Neuropeptide Y expression in phaeochromocytomas: Relative absence in tumours from patients with von Hippel-Lindau syndrome

Journal of Endocrinology

Volumn 193, Issue 2, 2007, Pages 225-233

  Cleary, Susannah ^a,b   Phillips, Jacqueline K ^b   Huynh, Thanh Truc ^a   Pacak, Karel ^c   Elkahloun, Abdel G ^d   Barb, Jennifer ^e   Worrell, Robert A ^f   Goldstein, David S ^a   Eisenhofer, Graeme ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b MURDOCH UNIVERSITY   (Australia)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; MESSENGER RNA; NEUROPEPTIDE Y; NORADRENALIN; PHENYLETHANOLAMINE N METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CATECHOLAMINE RELEASE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PHEOCHROMOCYTOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIPPLE SYNDROME; VON HIPPEL LINDAU DISEASE; ADRENAL TUMOR; ANALYSIS OF VARIANCE; CHEMISTRY; COMPARATIVE STUDY; GENETICS; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL MODEL;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; ANALYSIS OF VARIANCE; FEMALE; HIPPEL-LINDAU DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEUROPEPTIDE Y; PHENYLETHANOLAMINE N-METHYLTRANSFERASE; PHEOCHROMOCYTOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 34250317782     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-06-0138     Document Type: Article

References (30)

1. Adrian TE, Allen JM, Terenghi G, Bacarese-Hamilton AJ, Brown MJ, Polak JM & Bloom SR 1983 Neuropeptide Y in phaeochromocytomas and ganglioneuroblastomas. Lancet 2 540-542.
2. Barreto-Estrada JL, Medina-Ortiz WE & Garcia-Arraras JE 2003 The morphological and biochemical response of avian embryonic sympatho-adrenal cells to nerve growth factor is developmentally regulated. Brain Research. Developmental Brain Research 144 1-8.
3. Bornstein SR & Gimenez-Roqueplo AP 2006 Genetic testing in pheochromocytoma: increasing importance for clinical decision making. Annals of the New York, Academy of Sciences 1073 94-103.
4. Bravo EL 2002 Pheochromocytoma: an approach to antihrypertensive management. Annals of the New York Academy of Sciences 970 1-10.
5. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM & Pacak K 2006 High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. Journal of Clinical Endocrinology and Metabolism 91 4505-4509.
6. Cleary S, Brouwers FM, Eisenhofer G, Pacak K, Christie DL, Lipski J, McNeil AR & Phillips JK 2005 Expression of the noradrenaline transporter (NAT) and phenylethanolamine N-methyltransferase (PNMT) in normal human adrenal gland and phaeochromocytoma. Cell and Tissue Research 322 443-453.
7. Connell JM, Corder R, Asbury J, Macpherson S, Inglis GC, Lowry P, Burt AD & Semple PF 1987 Neuropeptide Y in multiple endocrine neoplasia: release during surgery for phaeochromocytoma. Clinical Endocrinology 26 75-84.
8. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JW et al. 2001 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. Journal of Clinical Endocrinolo1gy and Metabolism 86 1999-2008.
9. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS & Elkahloun AG 2004 Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocrine-Related Cancer 11 897-911.
10. Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, Brouwers FM & Pacak K 2005 Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of free metanephrines. Clinical Chemistry 51 735-744.
11. Eurin J, Barthelemy C, Masson F, Maistre G, Soualmia H, Noe E, Sarfati E, Eurin B & Carayon A 2000 Release of neuropeptide Y and hemodynamic changes during surgical removal of human pheochromocytomas. Regulatory Peptides 86 95-102.
12. Grouzmann E, Comoy E & Bohuon C 1989 Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 68 808-813.
13. Grouzmann E, Fathi M, Gillet M, de Torrente A, Cavadas C, Brunner H & Buclin T 2001 Disappearance rate of catecholamines, total metanephrines, and neuropeptide Y from the plasma of patients after resection of pheochromocytoma. Clinical Chemistry 47 1075-1082.
14. Henion PD & Landis SC 1990 Asynchronous appearance and topographic segregation of neuropeptide-containing cells in the developing rat adrenal medulla. Journal of Neuroscience 10 2886-2896.
15. Huynh TT, Pacak K, Brouwers FM, Abu-Asab MS, Worrell RA, Walther MM, Elkahloun AG, Goldstein DS, Cleary S & Eisenhofer G 2005 Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. European Journal of Endocrinology 153 551-563.
16. Koch CA, Mauro D, Walther MM, Linehan WM, Vortmeyer AO, Jaffe R, Pacak K, Chrousos GP, Zhuang Z & Lubensky IA 2002 Pheochromocytoma in von Hippel-Lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocrine Pathology 13 17-27.
17. Kuch-Wocial A, Slubowska K, Kostrubiec M, Pasierski T, Januszewicz W, Switalska H, Wocial B & Pruszczyk P 2004 Plasma neuropeptide Y immunoreactivity influences left ventricular mass in pheochromocytoma. Clinica Chimica Acta 345 43-47.
18. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG Jr et al. 2005 Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8 155-167.
19. Livak KJ & Schmittgen TD 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 402-408.
20. Lundberg JM, Hokfelt T, Hemsen A, Theodorsson-Norheim E, Pernow J, Hamberger B & Goldstein M 1986 Neuropeptide Y-like inummoreactivity in adrenaline cells of adrenal medulla and in tumors and plasma of pheochromocytoma patients. Regulatory Peptides 13 169-182.
21. Minth-Worby CA 1994 Transcriptional regulation of the human neuropeptide Y gene by nerve growth factor. Journal of Biological Chemistry 269 15460-15468.
22. O'Hare MM & Schwartz TW 1989 Expression and precursor processing of neuropeptide Y in human pheochromocytoma and neuroblastoma tumors. Cancer Research 49 7010-7014.
23. Pance A, Livesey FJ & Jackson AP 2006 A role for the transcriptional repressor REST in maintaining the phenotype of neurosecretory-deficient PC12 cells. Journal of Neurochemistry 99 1435-1444.
24. Parmer RJ & Zinder O 2002 Catecholaminergic pathways, chromaffin cells, and human disease. Annals of the New York Academy of Sciences 971 497-505.
25. deS Senarayake P, Denker J, Bravo EL & Graham RM 1995 Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. Journal of Clinical Investigation 96 2503-2509.
26. Spinazzi R, Andreis PG & Nussdorfer GG 2005 Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review). International Journal of Molecular Medicine 15 3-13.
27. Ullman B, Pernow J, Lundberg JM, Astrom H & Bergfeldt L 2002 Cardiovascular effects and cardiopulmonary plasma gradients following intravenous infusion of neuropeptide Y in humans: negative dromotropic effect on atrioventricular node conduction. Clinical Science 103 535-542.
28. Vogel TW, Brouwers FM, Lubensky IA, Vortmeyer AO, Weil RJ, Walther MM, Oldfield EH, Linehan WM, Pacak K & Zhuang Z 2005 Differential expression of erythropoietin and its receptor in von Hippel-Lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas. Journal of Clinical Endocrinololgy and Metabolism 90 3747-3751.
29. Walther MM, Reiter R, Keiser HR, Choyke PL, Venzon D, Hurley K, Gnarra JR, Reynolds JC, Glenn GM, Zbar et al. 1999 Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives into natural history of pheochromocytoma. Journal of Urology 162 659-664.
30. Woltensberger M, Forssmann WG & Reinecke M 1995 Localization and coexistence of atrial natriuretic peptide (ANP) and neuropeptide Y (NPY) in vertebrate adrenal chromaffin cells immunoreactive to TH, DBH and PNMT. Cell and Tissue Research 280 267-276.